Enterprise
Moderna and Merck Say mRNA Cancer Vaccine Succeeded in Phase 3 Melanoma Trial
Moderna and Merck say their personalised mRNA cancer therapy met key Phase 3 goals in melanoma, reducing the risk of recurrence and distant metastasis.
1 article
Moderna and Merck say their personalised mRNA cancer therapy met key Phase 3 goals in melanoma, reducing the risk of recurrence and distant metastasis.
Written by the reporters who cover each beat. Unsubscribe in one click.